Acuta Capital Partners’s Viridian Therapeutics VRDN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | – | Sell |
-199,433
| Closed | -$2.59M | – | 49 |
|
|
2024
Q2 | $2.59M | Hold |
199,433
| – | – | 2.19% | 18 |
|
|
2024
Q1 | $3.49M | Sell |
199,433
-82,067
| -29% | -$1.44M | 2.27% | 18 |
|
|
2023
Q4 | $6.13M | Buy |
281,500
+57,161
| +25% | +$1.24M | 3.45% | 11 |
|
|
2023
Q3 | $3.44M | Sell |
224,339
-368
| -0.2% | -$5.65K | 2.31% | 16 |
|
|
2023
Q2 | $5.35M | Buy |
224,707
+56,707
| +34% | +$1.35M | 3.62% | 9 |
|
|
2023
Q1 | $4.27M | Sell |
168,000
-228,500
| -58% | -$5.81M | 3.15% | 15 |
|
|
2022
Q4 | $11.6M | Buy |
396,500
+33,765
| +9% | +$986K | 7.13% | 2 |
|
|
2022
Q3 | $7.44M | Buy |
362,735
+128,709
| +55% | +$2.64M | 3.2% | 10 |
|
|
2022
Q2 | $2.71M | Sell |
234,026
-105,974
| -31% | -$1.23M | 1.51% | 22 |
|
|
2022
Q1 | $6.29M | Buy |
340,000
+22,000
| +7% | +$407K | 2.94% | 11 |
|
|
2021
Q4 | $6.29M | Buy |
318,000
+182,193
| +134% | +$3.6M | 2.64% | 13 |
|
|
2021
Q3 | $2.23M | Buy |
+135,807
| New | +$2.23M | 0.79% | 32 |
|